文献速递前列腺癌前列腺增生与排尿功能障碍

5α-还原酶抑制剂对前列腺mpMRI特征及癌检出分区影响

Prostate zonal impact of 5α-reductase inhibitors on multiparametric MRI characteristics and detection of prostate cancer.
PubMed 文献 · BJU Int · 2025-11-05

该多中心回顾性研究纳入718例患者的1108个PI-RADS 3-5病灶,评估5α-还原酶抑制剂(5-ARI)对mpMRI特征及临床显著前列腺癌(csPCa)检出的影响。5-ARI使用与靶向活检csPCa检出几率显著降低相关(OR 0.32,95%CI 0.18-0.57),外周带病灶降低更明显(OR 0.20,95%CI 0.05-0.68),移行带无统计学意义。

要点

  • 5-ARI使用与MRI靶向活检csPCa检出率降低相关(OR 0.32)。
  • 外周带病灶csPCa检出降低更显著(OR 0.20),移行带无统计学意义。
  • 5-ARI使用者外周带病灶ADC值更高、病灶可见度更低,或致假阳性增加。

核心结论

  • 5-ARI治疗与MRI靶向活检csPCa检出降低相关,尤其在外周带病灶,可能归因于ADC值升高和病灶可见度降低,提示5-ARI患者mpMRI假阳性可能增加。

研究设计与样本

  • 多中心回顾性队列,纳入718例患者的1108个PI-RADS v2评分3-5病灶,均行MRI靶向活检。
  • 其中66个来自5-ARI治疗患者的病灶与未治疗患者病灶匹配,由经验丰富放射科医生盲法独立审阅。
  • 定量测量每个病灶及外周带、移行带的表观扩散系数(ADC)值。

主要发现

  • 1108个病灶中90个(8%)来自mpMRI前接受5-ARI治疗≥3个月的患者。
  • 多变量分析显示5-ARI使用与靶向活检csPCa检出几率显著降低相关(OR 0.32,95%CI 0.18-0.57)。
  • 分层分析显示外周带病灶csPCa检出显著降低(OR 0.20,95%CI 0.05-0.68),移行带无统计学意义(OR 0.38,95%CI 0.11-1.18)。
  • 盲法影像审阅显示5-ARI使用者外周带病灶平均ADC值更高(869 vs 765 mm2/s;P = 0.04),病灶可见度更低(P = 0.027)。
  • 移行带未见显著影像学差异。

临床怎么用

  • 对接受5-ARI治疗的患者解读mpMRI时,应意识到外周带病灶csPCa检出可能降低、假阳性可能增加。
  • 5-ARI使用者外周带病灶ADC值升高和可见度降低可能影响PI-RADS评分判读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the impact of 5α-reductase inhibitors (5-ARIs) on multiparametric magnetic resonance imaging (mpMRI) features of Prostate Imaging-Reporting and Data System (PI-RADS) lesions and their influence on the detection of clinically significant prostate cancer (csPCa), with a focus on differences between prostate zones. PATIENTS AND METHODS: We retrospectively reviewed data from 1108 PI-RADS version 2 score 3-5 lesions in 718 patients across a multi-institutional cohort, all of whom underwent magnetic resonance imaging (MRI)-targeted biopsy. A subset of 66 lesions from patients receiving 5-ARI therapy was matched to lesions from untreated patients and independently reviewed by an experienced radiologist in a blinded fashion. Apparent diffusion coefficient (ADC) values were quantified for each lesion and for peripheral and transition zones. RESULTS: Among the 1108 lesions, 90 (8%) were in patients on 5-ARI therapy for ≥3 months prior to mpMRI. Multivariable analysis demonstrated that 5-ARI use was associated with significantly reduced odds of detecting csPCa on targeted biopsy (odds ratio [OR] 0.32, 95% confidence interval [CI] 0.18-0.57). Stratified analysis revealed a pronounced reduction in csPCa detection in peripheral zone lesions (OR 0.20, 95% CI 0.05-0.68), but not in transition zone lesions (OR 0.38, 95% CI 0.11-1.18). Blinded radiological review showed higher mean ADC values in peripheral zone lesions among 5-ARI users (869 vs 765 mm2/s; P = 0.04) and lower lesion conspicuity (P = 0.027). There were no significant imaging differences in the transition zone. CONCLUSIONS: Treatment with 5-ARIs is associated with decreased detection of csPCa on MRI-targeted biopsy, especially for peripheral zone lesions. These effects may be attributable to increased ADC values and reduced lesion conspicuity, suggesting a potential increase in false-positive mpMRI findings in patients receiving 5-ARIs.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Das A, Bigarella M, Brackman K, et al. Prostate zonal impact of 5α-reductase inhibitors on multiparametric MRI characteristics and detection of prostate cancer. BJU Int. 2025. PMID: 41190378. doi:10.1111/bju.70067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。